Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZFPM1 antisense RNA 1 (ZFPM1-AS1)
- Target
- ZFPM1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Non-coding RNA, Other
01
Overview
ZFPM1 antisense RNA 1 (ZFPM1-AS1) is a long non-coding RNA transcribed from chromosome 16, antisense to the ZFPM1 gene[4]. It does not encode a protein but instead regulates gene expression post-transcriptionally, predominantly by acting as a competitive endogenous RNA that sequesters microRNAs, thereby influencing the expression of genes implicated in cell proliferation, apoptosis, invasion, and metastasis of several cancers[1][2]. Elevated levels of ZFPM1-AS1 are frequently observed in various tumor types, including gastric, lung, and liver cancers, and are generally associated with poor clinical outcomes and altered immune infiltration[2]. Its expression has also been linked to chemotherapeutic drug sensitivity and may serve as a prognostic or predictive biomarker in oncology[2].
- Other names
- ZFPM1-AS1
02
Mechanism of action
ZFPM1-AS1 modulates cell behavior by: - Acting as a competing endogenous RNA (ceRNA) for microRNAs (e.g., miR-515) - Regulating oncogenic pathways such as the Wnt/β-catenin pathway
03
Biological functions
Regulation of gene expressionRegulation of cell proliferationRegulation of apoptosisModulation of cell signaling pathways
04
Disease associations
Cancer (oncogenic lncRNA, implicated in multiple tumor types)Possible roles in chemoresistance
05
Safety considerations
None directly applicable. As a non-coding RNA with no direct druggability, safety issues would only pertain to potential therapeutic interventions (e.g., RNA-based therapies), which are investigational.
06
Biomarkers
Potential role as a biomarker for: - Cancer prognosis (elevated expression indicates worse overall or disease-specific survival in several tumor types)Predicting response or resistance to chemotherapy (5-FU, oxaliplatin, cisplatin)
Beyond the preview
Go deeper on ZFPM1 antisense RNA 1 (ZFPM1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZFPM1 antisense RNA 1 (ZFPM1-AS1).